ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 23.5 | 6.3 | 5.4 |
| Other income | 0.5 | 0.9 | 1.1 |
| Total income | 24.1 | 7.3 | 6.5 |
| Profit before exceptional items & tax | 18.2 | 0.4 | 1.4 |
| Profit before tax | 18.2 | 0.4 | 1.4 |
| Net profit | 13.0 | -1.7 | 1.0 |
| Operating margin | 75.5% | 5.5% | 21.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1200.00% |
|---|---|
| Revenue, year on year | +335.20% |
| Operating profit, year on year | +5800.00% |
| Operating profit, quarter on quarter | +3640.00% |
BSE results filing, NSE: RELISH. Figures extracted from the filing.
Shukra Pharmaceuticals Ltd: key numbers
- Share price
- ₹83.19
- Market cap
- ₹3,681 Cr
- Revenue (annual)
- ₹56.73 Cr
- Net profit (annual)
- ₹22.06 Cr
- P/E (TTM)
- 83.1×Sector 43.8×
- Promoter holding
- 51.15%+0.19% QoQ
- FII holding
- 0.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shukra Pharmaceuticals Ltd
All →Shukra Pharmaceuticals Preferential Issue
Shukra Pharmaceuticals allotted 17.35 lakh preferential equity shares at Rs 35.56 to five investors. The raise totals about Rs 6.17 Crore.
- Value
- ₹6.17 Cr
Shukra Pharmaceuticals Other Announcement
Shukra Medtech confirmed no deviation in the use of funds from its preferential convertible warrant issue. The company received ₹10.46 Crore, 75% of the consideration, from allottees.
- Value
- ₹10.46 Cr
Shukra Pharmaceuticals Q2 FY27 Results: Net Profit ₹12.7 Cr, Up 429.2% YoY
Shukra Pharmaceuticals Ltd reported revenue from operations of ₹44.2 Cr (+649.2% YoY) and net profit of ₹12.7 Cr (+429.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹12.7 Cr · +429.2% YoY
Shukra Pharmaceuticals Board Meeting Date
Shukra Medtech Limited has scheduled a board meeting on November 3, 2026, to consider and approve its unaudited financial results for the quarter ended September 2026.
Shukra Pharmaceuticals Other Announcement
Shukra Medtech submitted a revised CA certificate to NSE for its name and symbol change application. The filing requests final exchange approval for the corporate rename.
Shukra Pharmaceuticals Other Announcement
Shukra Pharmaceuticals Limited has submitted the certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.